The global respiratory disease testing market size is expected to reach USD 7.75 billion by 2030, registering a CAGR of 2.8% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of respiratory diseases. As per Forum of International Respiratory Societies, more than 200 million people across the globe suffered from Chronic Obstructive Pulmonary Disease (COPD) and 235 million suffered from asthma in 2014. In addition, the source stated that more than 50 million people struggle with occupational lung diseases annually. Thus, constantly growing target patient population is anticipated to drive the growth.
The adoption of innovative technologies, such as Computed Tomography (CT), for COPD diagnosis is expected to drive the growth. The other new technology in acute medical management of COPD is pulse oximeter that is used for outpatient monitoring. Airway management plays a main role in testing and management of COPD. Also, with recent technological innovations, there has been a 12.1 % increase in the use of Noninvasive Mechanical Ventilation (NIV) for management of COPD. Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the respiratory disease testing/diagnostics market.
Request a free sample copy or view report summary: Respiratory Disease Testing Market Report
Growing prevalence of respiratory diseases and rapid technological advancements are two of the major factors expected to propel the market growth
Based on products, imaging tests held the largest share in 2022 due to rapid development and adoption of innovative technologies
Based on application, tuberculosis was the largest market in 2022 owing to rising prevalence of the disease globally
Based on end-use, hospitals segment held the largest share in 2022 and is anticipated to grow over the forecast period due to an increase in hospitalization and a growing preference for hospital treatment
North America dominated the respiratory disease testing market in 2022. Growing prevalence of respiratory diseases such as COPD, & asthma, increasing demand for early diagnosis, and rising awareness amongst patients about the benefits of early diagnosis are responsible for the dominance
Asia Pacific region is expected to grow at the fastest rate during the forecast period. This growth can be attributed to various factors, such as improving healthcare infrastructure and increasing patient awareness regarding the availability of new diagnostic techniques for respiratory diseases, such as COPD & asthma
Some of the major players competing in this market include, but are not limited to, Becton Dickinson (Carefusion Corporation); Koninklijke Philips N.V. (Respironics); ResMed Company; Fischer & Paykel; and Medtronic. These players are strong brands in the market as they have elaborate product portfolios in respiratory disease diagnostics market
Grand View Research has segmented the global respiratory disease testing market on the basis of product, application, end-use, and region:
Respiratory Disease Testing Market Product Outlook (Revenue, USD Million, 2018 - 2030)
Imaging Tests
Respiratory Measurement Devices
Blood Gas Test
Others
Respiratory Disease Testing Market Application Outlook (Revenue, USD Million, 2018 - 2030)
Chronic Obstructive Pulmonary Disease
Lung Cancer
Asthma
Tuberculosis
Other
Respiratory Disease Testing Market End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospital
Physicians Clinic
Clinical Laboratories
Other
Respiratory Disease Testing Market Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Kuwait
List of Key Players in the Respiratory Disease Testing Market
Abbott
BD
Koninklijke Philips N.V.
ResMed
Fisher & Paykel Appliances Ltd.
Medtronic
BIOMÉRIEUX
Carestream Health
SDI Diagnostics
Siemens Healthcare GmbH
"The quality of research they have done for us has been excellent..."